Lenalidomide is an immunomodulatory agent that belongs to the class of thalidomide analogues and has anti angiogenic and anti-tumor properties.

1、 Drug name

1. Common name: Lenalidomide

2. Product Name: REVLIMID ®

3. Dosage form: Capsule

2、 Indications

Suitable for the following adult patients:

1. Multiple myeloma (MM): in combination with dexamethasone; Or as a maintenance therapy after autologous hematopoietic stem cell transplantation.

2. Myelodysplastic syndrome (MDS) with 5q deficiency: used to treat transfusion dependent anemia caused by low-risk or moderate risk type 1 MDS.

3. Mantle cell lymphoma (MCL): a patient who has experienced recurrence or progression after receiving two previous treatments, one of which includes bortezomib.

4. Follicular lymphoma (FL) or marginal zone lymphoma (MZL): Used in combination with rituximab for previously treated patients.

Note: Not recommended for non clinical trial patients with chronic lymphocytic leukemia (CLL).

3、 Specifications and characteristics

1. Specifications: 15mg, 25mg.

2. Appearance: Capsule, color varies depending on specifications.

4、 Main components

1. Active ingredient: Lenalidomide.

2. Accessories: anhydrous lactose, microcrystalline cellulose, cross-linked carboxymethyl cellulose sodium, magnesium stearate, etc.

5、 Usage and dosage

1. MM combination therapy: 25mg once daily, taken orally from day 1-21, with a cycle of 28 days.

2. Maintenance treatment after MM transplantation: 10mg once daily, taken continuously for 28 days per cycle.

3. MDS: 10mg once daily.

4. MCL: 25mg once daily, taken orally from day 1-21, with a cycle of 28 days.

5. FL/MZL: 20mg once daily, taken orally from day 1-21, for a maximum of 12 cycles.

6. Patients with kidney damage need to adjust the starting dose based on creatinine clearance rate.

6、 Dose adjustment

Discontinue, reduce, or discontinue dosage based on blood routine results (platelet count, neutrophil count) and non hematological toxicity.

7、 Medication precautions

1. Dosage: Take at approximately the same time every day, either with food or on an empty stomach.

2. Capsules should be swallowed whole and should not be opened, chewed, or crushed.

3. Missing service handling: If the missed service time is less than 12 hours, it can be immediately replenished; If it exceeds 12 hours, skip this dose and take it normally the next day. Do not take double the dose at once.

4. If vomiting occurs, it should not be taken again. Continue taking the next dose according to the original plan.

5. If in contact with the contents of the capsule, immediately wash the skin with soap and water or rinse the mucous membrane with water.

8、 Medication for special populations

1. Pregnant women: prohibited, there is a risk of teratogenicity and embryo death.

2. Breastfeeding period: It is not recommended to breastfeed.

3. Women/Men of childbearing age: Strict contraceptive measures must be taken, and blood and sperm donation are prohibited during treatment and within 4 weeks after discontinuation of medication.

4. Elderly people: need to be closely monitored, especially for kidney function and cardiovascular events.

5. Renal insufficiency: Adjust the dosage based on creatinine clearance rate, and in severe cases, reduce the dosage or adjust the dosing frequency.

9、 Adverse reactions

1. Common adverse reactions include:

(1) Hematological system: neutropenia, thrombocytopenia, anemia.

(2) Digestive system: diarrhea, constipation, nausea, vomiting.

(3) Systemic: fatigue, fever, peripheral edema.

(4) Infection: Upper respiratory tract infection, pneumonia, urinary tract infection.

(5) Other: rash, itching, muscle spasms, dizziness, headache, etc.

2. Serious adverse reactions include:

Venous/arterial thrombosis, hepatotoxicity, severe skin reactions, tumor lysis syndrome, secondary malignant tumors, etc.

10、 Contraindications

1. Pregnant women.

2. Those who are severely allergic to lenalidomide or any of its ingredients.

11、 Drug interactions

1. Digoxin: Co administration may increase its blood drug concentration, and regular monitoring is recommended.

2. Erythropoietin or estrogen containing therapy: may increase the risk of thrombosis and should be used with caution.

3. Warfarin: No significant interaction was found, but it is still recommended to monitor PT/INR.

12、 Storage method

1. Stored at 20 ° C-25 ° C (68 ° F-77 ° F), short-term storage at 15 ° C-30 ° C is allowed.

2. Keep out of reach of children.

3. Do not open or damage the capsule.

Lenalidomideinformation